查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1642673

2025-2033 年按给药途径、适应症、配销通路和地区分類的特种仿製药市场报告

Specialty Generics Market Report by Route of Administration, Indication, Distribution channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 127 Pages | 商品交期: 2-3个工作天内

价格

2024年全球特种仿製药IMARC Group规模达818亿美元。推动市场发展的因素有很多，包括旨在利用能力、资源和市场影响力的策略合作数量不断增加、线上药局和远距医疗平台的发展以及有利的政府措施。

特种仿製药是指高成本品牌特用药物的仿製药。这些药物用于治疗复杂的慢性疾病，例如癌症、类风湿性关节炎、多发性硬化症和爱滋病毒。它们与传统仿製药的不同之处在于，它们通常是基于生物製剂的，需要特殊处理和给药（通常是注射剂），并且通常透过有限的网路进行分发。由于所涉及分子的复杂性质以及製造过程中使用的复杂工艺，特种仿製药的开发面临独特的挑战。因此，与传统仿製药相比，其审批监管途径可能更加严格。此外，特种仿製药在医疗保健领域具有巨大的潜力。它们以较低的成本为患者提供重要的治疗，同时也减轻了医疗保健系统的财务负担。

线上药局和远距医疗平台等先进分销管道的发展也推动了特种仿製药市场的成长。这些管道有助于轻鬆取得药物，确保即使是偏远地区的患者也能获得所需的药物。与此同时，政府医疗保健计划和私人付款人正在不断寻求控制不断上涨的医疗保健成本的策略。强调使用仿製药，特别是特种仿製药，是一个主要策略。因此，一些政府和保险公司现在鼓励或强制规定仿製药的处方，从而推动需求。此外，价格较实惠的特种仿製药已成为该地区许多人的首选，确保更多人口能够获得基本治疗。因此，这极大地支撑了市场。除此之外，针对更多利基和特殊条件的仿製药的生产正在为市场做出贡献。此外，旨在利用合作实体的能力、资源和市场影响力的策略合作正在创造积极的市场前景。

特殊仿製药市场趋势/驱动因素：

对经济实惠的医疗保健解决方案的需求不断增长

随着全球人口持续增长和非传染性疾病 (NCD) 负担的扩大，人们大力推动提供负担得起的医疗保健解决方案。特种仿製药产业具有独特的优势来满足这一需求。特种仿製药是品牌药物的生物等效版本，为患者和医疗保健系统提供创新药物的治疗功效，但成本较低。此外，日本、美国和许多欧洲国家等已开发国家的人口老化导致慢性病发生率增加。这些疾病通常需要长期且复杂的治疗方案，这可能会对个人和国家医疗保健系统造成经济负担。此外，在发展中国家，中产阶级人口的扩张及其对先进医疗保健解决方案的需求给现有基础设施带来了压力。

品牌药的专利到期

特种仿製药产业最重要的驱动因素之一是品牌药物专利的到期。当专利到期时，它为其他製造商生产和销售这些药物的仿製药打开了大门。鑑于仿製药的研发 (R&D) 成本通常低于新药，因此这些药物的定价更便宜，同时保持疗效。每年都有年销售额数十亿美元的药品失去专利保护。这为特种仿製药製造商提供了一个千载难逢的机会，可以进入拥有现成消费者基础的成熟市场。因此，这些药物的可及性将使更广泛的人群受益，特别是中低收入家庭的人群，从而对市场产生积极影响。

药物开发的技术进步

特种仿製药行业正在随着更广泛的製药行业的发展而发展。同时，药物开发和製造的最新技术进步使得更复杂的仿製药的生产成为可能，例如生物仿製药，而这在以前很难生产。此外，人工智慧和先进分析方法等工具简化了这些药物的研发 (R&D) 流程。这意味着专业仿製药製造商现在可以解决比以往更广泛的疾病和疾病。此外，製造流程的创新确保这些药物的生产品质稳定，并符合全球监管机构制定的严格标准。因此，它也为市场做出了贡献。

特殊仿製药市场细分：

依给药途径分类：

注射剂

口服

其他的

注射剂占市场主导地位

注射给药途径已成为特种仿製药产业的重要市场驱动力。这种增长可归因于慢性病和复杂医疗状况的日益普及。注射剂具有多种优点，包括精确剂量和快速起效，使其适合管理危急的健康状况。此外，某些品牌生物製剂和特种药物的专利到期为仿製药製造商提供具有成本效益的替代品进入市场打开了大门。此外，製药业对研发的日益关注导致了治疗效果改善的创新註射产品。这些市场驱动因素共同促进了注射剂给药途径在特种仿製药行业的成长和突出。

相反，由于消费者偏好的变化，口服给药途径作为特种仿製药行业的市场驱动因素发挥关键作用。许多患者喜欢口服製剂，因为易于给药，无需注射并减少潜在的不适。除此之外，大量需要长期治疗的慢性疾病和病症也促进了口服药物的普及。

按指示细分：

肿瘤学

自体免疫疾病

传染病

其他的

肿瘤学占市场主导地位

全球癌症盛行率持续上升，因此需要持续需求有效且负担得起的肿瘤治疗。随着越来越多的患者需要长期治疗，特种仿製药的可及性和成本效益对于改善癌症护理变得至关重要。此外，一些品牌肿瘤药物的专利到期为仿製药製造商进入市场提供了机会，在不影响品质的情况下提供更实惠的替代品。除此之外，研究和技术的进步促进了创新製剂和药物输送系统的开发，提高了肿瘤学仿製药的疗效和患者依从性。此外，旨在透过促进仿製药使用来减轻癌症负担的政府措施和政策进一步推动了市场成长。

另一方面，受包括疫情和大流行在内的全球传染病负担的影响，传染病给药途径已成为特种仿製药行业的关键市场驱动因素，这凸显了对有效且可及的治疗方案的迫切需要。

按配销通路划分：

零售药局

专业药房

医院药房

零售药局主导市场

零售药局配销通路作为特种仿製药行业的市场驱动力发挥关键作用，主要受到零售药局广泛存在的影响，确保向更广泛的患者群体方便、可及地分销特种仿製药。由于这些药房通常位于各个社区和街区，患者可以轻鬆获得处方药物，而不需要专门的医疗设施。此外，慢性病盛行率的上升以及对长期治疗选择的需求不断增长，放大了零售药局在提供特殊仿製药方面的重要性。此外，零售药局与医疗保健提供者建立的关係可以简化沟通和协作，促进高效的处方处理和病患照护。随着对特种仿製药的需求持续增长，零售药局在分销和患者支援方面的重要作用将加强该行业的扩张和关键药物的可及性。

按地区划分：

北美洲

美国

加拿大

欧洲

义大利

德国

西班牙

英国

法国

亚太

中国

印度

日本

韩国

拉丁美洲

巴西

墨西哥

中东和非洲

北美表现出明显的主导地位，占据最大的特种仿製药市场份额

该报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；欧洲（义大利、德国、法国、英国和西班牙）；亚太地区（日本、中国、印度和韩国）；拉丁美洲（巴西、墨西哥）；以及中东和非洲。报告称，北美占据最大的市场份额。

北美地区的发展受到慢性病和复杂医疗状况日益普及的推动。这导致对专业治疗方案的需求不断增长。特种仿製药以其具有成本效益的品牌特种药替代品，在有效管理这些疾病方面获得了关注。此外，某些品牌专科药物的专利到期为仿製药製造商进入市场创造了机会，为患者提供更实惠的治疗选择。此外，旨在促进仿製药使用的有利政府政策和措施也支持了北美特种仿製药产业的扩张。这些政策鼓励仿製药的使用，从而增加患者的可及性并节省医疗保健系统的整体成本。此外，研究和开发的进步导致推出具有改善治疗效果的创新专业仿製药，正在对市场产生积极影响。

竞争格局：

由于开发创新配方、药物输送系统和联合疗法以提高产品功效和患者依从性的研发投资不断增加，全球特种仿製药市场正在经历显着增长。确保遵守监管标准并获得各国卫生当局的必要批准是专业仿製药公司推出和行销其产品的关键方面。同时，产品组合的扩展涵盖更广泛的治疗领域，例如肿瘤学、免疫学和罕见疾病，以满足不同患者的需求，正在对市场产生积极影响。除此之外，公司还提供患者支持计划，为患者提供咨询、依从性援助和经济援助，从而改善患者的治疗效果和药物依从性。此外，与製药公司、研究机构和医疗保健组织的合作使特种仿製药公司能够获得新技术，从而为市场做出贡献。

该报告对市场竞争格局进行了全面分析。也提供了所有主要公司的详细资料。市场上的一些主要参与者包括：

梯瓦製药工业公司

阿康公司

迈兰公司

马林克罗特

山德士国际有限公司

辉瑞公司

太阳製药工业有限公司

威朗製药公司

阿波泰克斯公司

远藤国际有限公司

本报告回答的关键问题

  • 全球特种仿製药市场规模有多大
  • 推动全球特种仿製药市场的关键因素是什么
  • COVID-19 对全球特种仿製药市场有何影响
  • 基于给药途径的全球特种仿製药市场的划分是怎样的
  • 根据适应症，全球特种仿製药市场的细分情况如何
  • 基于配销通路的全球特种仿製药市场的细分是什么
  • 全球特种仿製药市场的关键区域有哪些
  • 谁是全球特种仿製药市场的主要参与者/公司

本报告回答的关键问题

  • 全球特种仿製药市场规模有多大？推动全球特种仿製药市场的关键因素是什么？
  • COVID-19 对全球特种仿製药市场有何影响？
  • 根据给药途径，全球特种仿製药市场的细分情况如何？
  • 根据此适应症，全球特种仿製药市场的细分情况如何？
  • 基于配销通路的全球特种仿製药市场的细分情况如何？
  • 全球特种仿製药市场的关键区域有哪些？
  • 全球特种仿製药市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：全球特种仿製药市场：简介

第 5 章：为什么特种仿製药如此有利可图？

第 6 章：全球特种仿製药市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场区隔：依给药途径
  • 市场区隔：依指标
  • 市场区隔：按配销通路
  • 市场区隔：按地区
  • 市场预测
  • SWOT分析
    • 概述
    • 优势
    • 弱点
    • 机会
    • 威胁
  • 价值链分析
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 主要市场驱动因素与成功因素

第 7 章：市场区隔：依管理途径

  • 可注射
    • 市场趋势
    • 市场预测
  • 口服
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：依迹象

  • 肿瘤学
    • 市场趋势
    • 市场预测
  • 自体免疫疾病
    • 市场趋势
    • 市场预测
  • 传染病
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按配销通路

  • 零售药局
    • 市场趋势
    • 市场预测
  • 专业药房
    • 市场趋势
    • 市场预测
  • 医院药房
    • 市场趋势
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 市场概况
    • 市场表现
    • 市场细分：按国家/地区
    • 市场预测
  • 欧洲
    • 市场概况
    • 市场表现
    • 市场细分：按国家/地区
    • 市场预测
  • 亚太地区
    • 市场概况
    • 市场表现
    • 市场细分：按国家/地区
    • 市场预测
  • 拉丁美洲
    • 市场概况
    • 市场表现
    • 市场细分：按国家/地区
    • 市场预测
  • 中东和非洲
    • 市场概况
    • 市场表现
    • 市场预测

第 11 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Teva Pharmaceuticals Industries
    • Akorn, Inc.
    • Mylan NV
    • Mallinckrodt
    • Sandoz International GmbH
    • Pfizer, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Valeant Pharmaceuticals
    • Apotex Corp.
    • Endo International plc.
Product Code: SR112024A1219

The global specialty generics market size reached USD 81.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 178.6 Billion by 2033, exhibiting a growth rate (CAGR) of 9.1% during 2025-2033. There are various factors that are driving the market, which include rising number of strategic collaborations aiming to leverage the capabilities, resources, and market presence, the evolution of online pharmacies and telemedicine platforms, and favorable government initiatives.

Specialty generics refer to generic versions of high-cost, brand-name specialty drugs. These medications are used to treat complex, chronic conditions such as cancer, rheumatoid arthritis, multiple sclerosis, and HIV. They differ from traditional generics in that they are typically biologic-based, require special handling and administration often injectables, and are often distributed through limited networks. The development of specialty generics presents unique challenges due to the intricate nature of the molecules involved and the complex processes used in their manufacturing. As a result, regulatory pathways for their approval can be more stringent compared to conventional generic drugs. In addition, specialty generics hold immense potential in healthcare. They offer patients access to vital treatments at a reduced cost, while also alleviating the financial burden on healthcare systems.

The evolution of advanced distribution channels, such as online pharmacies and telemedicine platforms, has also propelled the growth of the specialty generics market. These channels facilitate easy access to medications, ensuring patients in even remote locations can obtain the drugs they need. Along with this, government healthcare programs and private payers are continuously seeking strategies to contain escalating healthcare costs. Emphasizing the use of generic drugs, especially specialty generics, is a primary strategy. Therefore, several governments and insurance companies now incentivize or mandate the prescription of generics where available, thereby driving demand. In addition, specialty generics, being more affordably priced, have become the preferred choice for many in regions, ensuring essential treatments are within reach of larger segments of the population. Thus, this is significantly supporting the market. Apart from this, the production of generics for more niche, and specialized conditions is contributing to the market. Moreover, strategic collaborations aiming to leverage the capabilities, resources, and market presence of partnering entities are creating a positive market outlook.

Specialty Generics Market Trends/Drivers:

Increasing Demand for Affordable Healthcare Solutions

As the global population continues to rise and the burden of non-communicable diseases (NCDs) expands, there's a significant push to provide affordable healthcare solutions. The specialty generics industry is uniquely poised to address this demand. Specialty generics, which are bioequivalent versions of brand-name drugs, offer patients and healthcare systems the therapeutic efficacy of innovative medicines but at a reduced cost. Additionally, aging populations in various developed countries, such as Japan, the United States, and numerous European nations, are leading to an increased incidence of chronic diseases. These conditions often require prolonged and complex treatment regimens, which can be financially taxing for both individuals and national healthcare systems. Furthermore, in developing nations, the expansion of middle-class populations and their demand for advanced healthcare solutions is putting a strain on existing infrastructures.

Patent Expirations of Branded Drugs

One of the most significant drivers of the specialty generics industry is the expiration of patents for branded drugs. When patents expire, it opens the door for other manufacturers to produce and market generic versions of those medications. Given that research and development (R&D) costs for generics are typically lower than for novel drugs, these medications can be priced more affordably while maintaining therapeutic efficacy. Each year, drugs with billions of dollars in annual sales lose patent protection. This presents a golden opportunity for specialty generic manufacturers to tap into established markets with a ready consumer base. Thus, the accessibility of these medications then benefits the wider population, especially those in low-to-middle-income households, positively influencing the market.

Technological Advancements in Drug Development

The specialty generics industry is evolving with the broader pharmaceutical sector. Along with this, recent technological advancements in drug development and manufacturing are enabling the production of more complex generics, such as biosimilars, which were previously challenging to produce. In addition, tools, such as artificial intelligence and advanced analytical methodologies have streamlined the research and development (R&D) process for these drugs. This means that specialty generic manufacturers now address a broader range of diseases and conditions than ever before. Furthermore, innovations in manufacturing processes are ensuring that these drugs are produced with consistent quality, meeting the rigorous standards set by global regulatory bodies. As a result, it is also contributing to the market.

Specialty Generics Market Segmentation:

Breakup by Route of Administration:

Injectables

Oral

Others

Injectable dominates the market

The injectables route of administration has emerged as a significant market driver within the specialty generics industry. This growth can be attributed to the increasing prevalence of chronic diseases and complex medical conditions. Injectables offer advantages, including precise dosing and rapid onset of action, making them suitable for managing critical health conditions. In addition, the expiration of patents for certain branded biologics and specialty drugs has opened doors for generic manufacturers to enter the market with cost-effective alternatives. Moreover, the rising focus on research and development in the pharmaceutical sector has led to innovative injectable products with improved therapeutic outcomes. These market drivers collectively contribute to the growth and prominence of the injectables route of administration in the specialty generics industry.

On the contrary, the oral route of administration plays a pivotal role as a market driver within the specialty generics industry, due to the changing consumer preferences. Numerous patients prefer oral formulations due to ease of administration, eliminating the need for injections and reducing potential discomfort. Along with this, the vast array of chronic diseases and conditions requiring long-term treatment has contributed to the popularity of oral drugs.

Breakup by Indication:

Oncology

Autoimmune Diseases

Infectious Diseases

Others

Oncology dominates the market

The rising prevalence of cancer continues to rise globally, necessitating a constant demand for effective and affordable oncology treatments. With an increasing number of patients requiring long-term therapies, the accessibility and cost-effectiveness of specialty generics become essential in improving cancer care. In addition, the expiration of patents for several branded oncology drugs has opened opportunities for generic manufacturers to enter the market, offering more affordable alternatives without compromising on quality. Apart from this, advancements in research and technology have led to the development of innovative formulations and drug delivery systems, enhancing the efficacy and patient compliance of oncology generics. Moreover, government initiatives and policies aimed at reducing the burden of cancer by promoting generic drug usage have further propelled market growth.

On the other hand, the infectious diseases route of administration has emerged as a crucial market driver within the specialty generics industry, influenced by the ongoing global burden of infectious diseases, including outbreaks and pandemics, has underscored the urgent need for effective and accessible treatment options.

Breakup by Distribution channel:

Retail Pharmacies

Specialty Pharmacies

Hospital Pharmacies

Retail pharmacies dominates the market

The retail pharmacies distribution channel plays a pivotal role as a market driver within the specialty generics industry, primarily influenced by the widespread presence of retail pharmacies ensuring convenient and accessible distribution of specialty generic medications to a broader patient base. As these pharmacies are typically located in various communities and neighborhoods, patients can easily access their prescribed medications without the need for specialized healthcare facilities. In addition, the rising prevalence of chronic diseases and the growing demand for long-term treatment options have amplified the significance of retail pharmacies in delivering specialty generics. Furthermore, the retail pharmacies' established relationships with healthcare providers allow for streamlined communication and collaboration, facilitating efficient prescription processing and patient care. As the demand for specialty generics continues to grow, retail pharmacies' essential role in distribution and patient support is set to reinforce the industry's expansion and accessibility to critical medications.

Breakup by Region:

North America

United States

Canada

Europe

Italy

Germany

Spain

United Kingdom

France

Asia-Pacific

China

India

Japan

South Korea

Latin America

Brazil

Mexico

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest specialty generics market share

The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada); Europe (Italy, Germany, France, United Kingdom, and Spain); Asia Pacific (Japan, China, India, and South Korea); Latin America (Brazil, Mexico); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The North America region is driven by the increasing prevalence of chronic diseases and complex medical conditions. It is leading to a growing demand for specialized treatment options. Specialty generics, with their cost-effective alternatives to branded specialty drugs, have gained traction in managing these conditions effectively. Additionally, the expiration of patents for certain branded specialty medications has created opportunities for generic manufacturers to enter the market, providing patients with more affordable treatment options. In addition, favorable government policies and initiatives aimed at promoting the use of generic medications have supported the expansion of the specialty generics industry in North America. These policies encourage generic drug usage, leading to enhanced patient access and overall cost savings in the healthcare system. Moreover, advancements in research and development leading to the introduction of innovative specialty generics with improved therapeutic outcomes are positively influencing the market.

Competitive Landscape:

The global specialty generics market is experiencing significant growth due to the escalating investments in research and development to develop innovative formulations, drug delivery systems, and combination therapies to improve the efficacy and patient compliance of their products. Ensuring compliance with regulatory standards and obtaining necessary approvals from health authorities in various countries is a critical aspect for specialty generic companies to launch and market their products. Along with this, the expansion of product portfolios to cover a wider range of therapeutic areas, such as oncology, immunology, and rare diseases, to cater to diverse patient needs is positively influencing the market. Apart from this, companies are offering patient support programs that provide counseling, adherence assistance, and financial aid to patients, thereby improving patient outcomes and medication adherence. Furthermore, collaborating with pharmaceutical companies, research institutions, and healthcare organizations allows specialty generics companies to access new technologies is contributing to the market.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Teva Pharmaceuticals Industries

Akorn, Inc.

Mylan N.V.

Mallinckrodt

Sandoz International GmbH

Pfizer, Inc.

Sun Pharmaceutical Industries Ltd.

Valeant Pharmaceuticals

Apotex Corp.

Endo International plc

Key Questions Answered in This Report

  • 1. What is the size of the global specialty generics market?
  • 2. What are the key factors driving the global specialty generics market?
  • 3. What has been the impact of COVID-19 on the global specialty generics market?
  • 4. What is the breakup of the global specialty generics market based on the route of administration?
  • 5. What is the breakup of the global specialty generics market based on the indication?
  • 6. What is the breakup of the global specialty generics market based on the distribution channel?
  • 7. What are the key regions in the global specialty generics market?
  • 8. Who are the key players/companies in the global specialty generics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Global Specialty Generics Market: Introduction

5 Why are Specialty Generics So Lucrative?

6 Global Specialty Generics Market

  • 6.1 Market Overview
  • 6.2 Market Performance
  • 6.3 Impact of COVID-19
  • 6.4 Market Breakup by Route of Administration
  • 6.5 Market Breakup by Indication
  • 6.6 Market Breakup by Distribution Channel
  • 6.7 Market Breakup by Region
  • 6.8 Market Forecast
  • 6.9 SWOT Analysis
    • 6.9.1 Overview
    • 6.9.2 Strengths
    • 6.9.3 Weaknesses
    • 6.9.4 Opportunities
    • 6.9.5 Threats
  • 6.10 Value Chain Analysis
  • 6.11 Porters Five Forces Analysis
    • 6.11.1 Overview
    • 6.11.2 Bargaining Power of Buyers
    • 6.11.3 Bargaining Power of Suppliers
    • 6.11.4 Degree of Competition
    • 6.11.5 Threat of New Entrants
    • 6.11.6 Threat of Substitutes
  • 6.12 Key Market Drivers and Success Factors

7 Market Breakup by Route of Administration

  • 7.1 Injectable
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Oral
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Autoimmune Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Infectious Diseases
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Retail Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Specialty Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Hospital Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Overview
    • 10.1.2 Market Performance
    • 10.1.3 Market Breakup by Country
      • 10.1.3.1 United States
        • 10.1.3.1.1 Market Trends
        • 10.1.3.1.2 Market Forecast
      • 10.1.3.2 Canada
        • 10.1.3.2.1 Market Trends
        • 10.1.3.2.2 Market Forecast
    • 10.1.4 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Overview
    • 10.2.2 Market Performance
    • 10.2.3 Market Breakup by Country
      • 10.2.3.1 Italy
        • 10.2.3.1.1 Market Trends
        • 10.2.3.1.2 Market Forecast
      • 10.2.3.2 Germany
        • 10.2.3.2.1 Market Trends
        • 10.2.3.2.2 Market Forecast
      • 10.2.3.3 France
        • 10.2.3.3.1 Market Trends
        • 10.2.3.3.2 Market Forecast
      • 10.2.3.4 United Kingdom
        • 10.2.3.4.1 Market Trends
        • 10.2.3.4.2 Market Forecast
      • 10.2.3.5 Spain
        • 10.2.3.5.1 Market Trends
        • 10.2.3.5.2 Market Forecast
    • 10.2.4 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Overview
    • 10.3.2 Market Performance
    • 10.3.3 Market Breakup by Country
      • 10.3.3.1 Japan
        • 10.3.3.1.1 Market Trends
        • 10.3.3.1.2 Market Forecast
      • 10.3.3.2 China
        • 10.3.3.2.1 Market Trends
        • 10.3.3.2.2 Market Forecast
      • 10.3.3.3 India
        • 10.3.3.3.1 Market Trends
        • 10.3.3.3.2 Market Forecast
      • 10.3.3.4 South Korea
        • 10.3.3.4.1 Market Trends
        • 10.3.3.4.2 Market Forecast
    • 10.3.4 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Market Overview
    • 10.4.2 Market Performance
    • 10.4.3 Market Breakup by Country
      • 10.4.3.1 Brazil
        • 10.4.3.1.1 Market Trends
        • 10.4.3.1.2 Market Forecast
      • 10.4.3.2 Mexico
        • 10.4.3.2.1 Market Trends
        • 10.4.3.2.2 Market Forecast
    • 10.4.4 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Overview
    • 10.5.2 Market Performance
    • 10.5.3 Market Forecast

11 Competitive Landscape

  • 11.1 Market Structure
  • 11.2 Key Players
  • 11.3 Profiles of Key Players
    • 11.3.1 Teva Pharmaceuticals Industries
    • 11.3.2 Akorn, Inc.
    • 11.3.3 Mylan N.V.
    • 11.3.4 Mallinckrodt
    • 11.3.5 Sandoz International GmbH
    • 11.3.6 Pfizer, Inc.
    • 11.3.7 Sun Pharmaceutical Industries Ltd.
    • 11.3.8 Valeant Pharmaceuticals
    • 11.3.9 Apotex Corp.
    • 11.3.10 Endo International plc.

List of Figures

  • Figure 1: Global: Specialty Generics Market: Major Drivers and Challenges
  • Figure 2: Global: Specialty Generics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Specialty Generics Market: Breakup by Route of Administration (in %), 2024
  • Figure 4: Global: Specialty Generics Market: Breakup by Indication (in %), 2024
  • Figure 5: Global: Specialty Generics Market: Breakup by Distribution Channel (in %), 2024
  • Figure 6: Global: Specialty Generics Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Specialty Generics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 8: Global: Specialty Generics Industry: SWOT Analysis
  • Figure 9: Global: Specialty Generics Industry: Value Chain Analysis
  • Figure 10: Global: Specialty Generics Industry: Porter's Five Forces Analysis
  • Figure 11: Global: Specialty Generics Market (Administration through Injectables): Sales Value (in Billion USD), 2019 & 2024
  • Figure 12: Global: Specialty Generics Market (Administration through Injectables) Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 13: Global: Specialty Generics Market (Oral Administration): Sales Value (in Billion USD), 2019 & 2024
  • Figure 14: Global: Specialty Generics Market (Oral Administration) Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 15: Global: Specialty Generics Market (Other Routes of Administration): Sales Value (in Billion USD), 2019 & 2024
  • Figure 16: Global: Specialty Generics Market (Other Routes of Administration) Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 17: Global: Specialty Generics Market (Oncology): Sales Value (in Billion USD), 2019 & 2024
  • Figure 18: Global: Specialty Generics Market (Oncology) Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 19: Global: Specialty Generics Market (Autoimmune Diseases): Sales Value (in Billion USD), 2019 & 2024
  • Figure 20: Global: Specialty Generics Market (Autoimmune Diseases) Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 21: Global: Specialty Generics Market (Infectious Diseases): Sales Value (in Billion USD), 2019 & 2024
  • Figure 22: Global: Specialty Generics Market (Infectious Diseases) Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 23: Global: Specialty Generics Market (Other Indications): Sales Value (in Billion USD), 2019 & 2024
  • Figure 24: Global: Specialty Generics Market (Other Indications) Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 25: Global: Specialty Generics Market: Sales Through Retail Pharmacies (in Billion USD), 2019 & 2024
  • Figure 26: Global: Specialty Generics Market Forecast: Sales Through Retail Pharmacies (in Billion USD), 2025-2033
  • Figure 27: Global: Specialty Generics Market: Sales Through Specialty Pharmacies (in Billion USD), 2019 & 2024
  • Figure 28: Global: Specialty Generics Market Forecast: Sales Through Specialty Pharmacies (in Billion USD), 2025-2033
  • Figure 29: Global: Specialty Generics Market: Sales Through Hospital Pharmacies (in Billion USD), 2019 & 2024
  • Figure 30: Global: Specialty Generics Market Forecast: Sales Through Hospital Pharmacies (in Billion USD), 2025-2033
  • Figure 31: North America: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: North America: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: United States: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: United States: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Canada: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Canada: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Europe: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Europe: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Italy: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Italy: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Germany: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Germany: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: France: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: France: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: United Kingdom: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: United Kingdom: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Spain: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Spain: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Asia Pacific: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Asia Pacific: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Japan: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Japan: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: China: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: China: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: India: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: India: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: South Korea: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: South Korea: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Latin America: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Latin America: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Brazil: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Brazil: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Mexico: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Mexico: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Middle East and Africa: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Middle East and Africa: Specialty Generics Market: Breakup by Country (in %), 2024
  • Figure 67: Middle East and Africa: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033

List of Tables

  • Table 1: Global: Specialty Generics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Specialty Generics Market Forecast: Breakup by Route of Administration (in Billion USD), 2025-2033
  • Table 3: Global: Specialty Generics Market Forecast: Breakup by Indication (in Billion USD), 2025-2033
  • Table 4: Global: Specialty Generics Market Forecast: Breakup by Distribution Channel (in Billion USD), 2025-2033
  • Table 5: Global: Specialty Generics Market Forecast: Breakup by Region (in Billion USD), 2025-2033
  • Table 6: North America: Specialty Generics Market: Key Industry Highlights, 2024 and 2033
  • Table 7: Europe: Specialty Generics Market: Key Industry Highlights, 2024 and 2033
  • Table 8: Asia Pacific: Specialty Generics Market: Key Industry Highlights, 2024 and 2033
  • Table 9: Latin America: Specialty Generics Market: Key Industry Highlights, 2024 and 2033
  • Table 10: Middle East and Africa: Specialty Generics Market: Key Industry Highlights, 2024 and 2033
  • Table 11: Global: Specialty Generics Market Structure
  • Table 12: Global: Specialty Generics Market: Key Players